Investment
Features
FeesSafety
Academy
More
Pluang+

Compare T-Rex 2X Long MSTR Daily Target ETF (MSTU) vs Smith & Nephew plc (SNN) Price & Performance

T-Rex 2X Long MSTR Daily Target ETFTrade
Smith & Nephew plcTrade

Price performance (Past 24H)

Key statistics

T-Rex 2X Long MSTR Daily Target ETF vs Smith & Nephew plc — how do they compare? T-Rex 2X Long MSTR Daily Target ETF trades at $39.7 (market cap $809.00M), while Smith & Nephew plc trades at $27.24 (market cap $11.10B). The key difference: Smith & Nephew plc is far larger — about 13.7× T-Rex 2X Long MSTR Daily Target ETF's market cap, and Smith & Nephew plc pays a 2.95% dividend while T-Rex 2X Long MSTR Daily Target ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold T-Rex 2X Long MSTR Daily Target ETF for 18 Days and Smith & Nephew plc for 121 Days on average.

MSTUSNN
Market Cap
$809.00M$11.10B
Volume
4,577,4651,051,703
Sector
Leveraged / InverseHealth
52-Week High
$432.00$37.17
52-Week Low
$14.60$26.42
Typical Hold Time
18 Days121 Days
Enterprise Value
—$14.13B
Dividend Yield
—2.95%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

T-Rex 2X Long MSTR Daily Target ETF

MSTU is trading at $38.33, down 2.84% on the day, with a bearish technical outlook as moving averages signal selling pressure. The stock recently underwent a 10:1 reverse stock split effective August 24, 2026, and declared a $0.29 dividend payable August 26, 2026. Key support levels are at $37 and $35, while resistance sits at $40 and $41.

The outlook remains cautious due to the bearish technical setup and lack of current fundamental data. Investment opportunities hinge on the company's ability to demonstrate improved financial performance post-reverse split, while risks include continued technical weakness and potential volatility from the leveraged ETF structure.

Smith & Nephew plc

SNN trades at $26.96, up 0.26% on the day, but near its 52-week low amid a bearish technical signal. Recent earnings have mostly beaten expectations, with Q2 2026 EPS of $0.946 exceeding the $0.939 estimate. Revenue grew to $6.16B in 2025, and net income margin improved to 10.08%. The company continues to launch new medical products, such as the EVOS PELVIC System, to drive growth.

The outlook is mixed; strong fundamentals and product innovation support long-term value, but near-term price pressure and analyst caution pose risks. Investors should weigh robust profitability against competitive threats and recent management changes.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

MSTU
43% Buy57% Sell
Avg holding period · 18 Days
SNN

No sentiment data available yet.

About T-Rex 2X Long MSTR Daily Target ETF

MSTU is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bullish (long) position in MSTR, a company known for its significant Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.

Read more on MSTU →

About Smith & Nephew plc

Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.

Read more on SNN →